NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - MajesTEC-3
Updated: Feb 10
MajesTEC-3
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3)
64007957MMY3001
NCT05083169: A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3)
Relapsed & Refractory Multiple Myeloma
The purpose of this study is to compare the efficacy of teclistamab-daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with bortezomib and dexamethasone (DVd).
Sponsor
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT05083169
Official Title: A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
First Posted : October 19, 2021
Click here to see details on ClinicalTrials.gov
Drug: Daratumumab ( Darzalex)
Drug: Pomalidomide ( Pomalyst)
Drug: Dexamethasone ( Decadron)
Drug: Bortezomib ( Velcade)
Drug: Teclistamab
- Alabama: University of Alabama at Birmingham
- California: City of Hope Duarte
- Connecticut: Yale University New Haven
- Minnesota: Mayo Clinic Rochester Minnesota
- New Jersey: Hackensack University Medical Center
- Ohio: Cleveland Clinic Ohio
- Pennsylvania: University of Pittsburgh Medical Center
- Texas: UT Southwestern Medical Center Dallas
- Washington: Seattle Cancer Care Alliance
- Wisconsin: Medical College of Wisconsin Milwaukee
Locations
United States, Alabama
United States, California
United States, Connecticut
United States, Georgia
United States, Massachusetts
United States, Michigan
United States, Minnesota
United States, New Jersey
United States, New York
United States, Ohio
United States, Oregon
United States, Pennsylvania
United States, South Carolina
United States, Tennessee
United States, Texas
United States, Utah
United States, Washington
United States, Wisconsin
Canada
Canada, Alberta
Canada, British Columbia
Canada, Nova Scotia
Canada, Ontario
Canada, Quebec
Argentina
Brazil
China
Europe
United Kingdom
France
Germany
Italy
Netherlands
Spain
Belgium
Denmark
Greece
Poland
Sweden
Asia
Japan
Korea, Republic of
Russian Federation
Taiwan
RELATED POSTS
TECLISTAMAB STUDIES:
NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma (MajesTEC1)
NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)
NCT05243797: Phase 3: Tec + Len Vs Len Alone in NDMM as Maintenance Therapy Post ASCT (MajesTEC-4)
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)
TALQUETAMAB STUDIES:
NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1
NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma
NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma
TECLISTAMAB AND TALQUETAMAB STUDIES:
NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma
NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2